New formulation of prostate drug put to the test

NCT ID NCT07715305

Not yet recruiting Disease control Sponsor: Addpharma Inc. Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This trial compares a new formulation (AD-116A) of a drug used for benign prostatic hyperplasia to the original version (AD-1161) in healthy adult male volunteers. The goal is to see if the two formulations are bioequivalent—meaning they work the same way in the body. Participants receive a single dose of each in random order under fasting conditions, and researchers measure drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AD-116A (a new formulation of a drug for benign prostatic hyperplasia)
What this could lead to: If AD-116A proves bioequivalent, it could offer a new formulation option for treating benign prostatic hyperplasia.
What could go wrong: This is an early-phase study in healthy volunteers, not patients, so results may not predict real-world effectiveness or safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BENIGN PROSTATIC HYPERPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

benign prostatic hyperplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BENIGN PROSTATIC HYPERPLASIA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

H PLUS YANGJI HOSPITAL, Seoul

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.